Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Altered Blood-Brain Barrier and Blood-Spinal Cord Barrier Dynamics in Amyotrophic Lateral Sclerosis: Impact on Medication Efficacy and Safety
  • Yijun Pan,
  • Joseph Nicolazzo
Yijun Pan
Monash Institute of Pharmaceutical Sciences, Monash University

Corresponding Author:[email protected]

Author Profile
Joseph Nicolazzo
Monash Institute of Pharmaceutical Sciences, Monash University
Author Profile

Abstract

The access of drugs into the central nervous system (CNS) is regulated by the blood-brain barrier (BBB) and blood-spinal cord barrier (BSCB). A large body of evidence supports perturbation of these barriers in neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease. Modifications to the BBB and BSCB are also reported in amyotrophic lateral sclerosis (ALS), albeit these modifications have received less attention relative to those in other neurodegenerative diseases. Such alterations to the BBB and BSCB have the potential to impact on CNS exposure of drugs in ALS, modulating the effectiveness of drugs intended to reach the brain and the toxicity of drugs that are not intended to reach the brain. Given the clinical importance of these phenomena, this review will summarise reported modifications to the BBB and BSCB in ALS, discuss their impact on CNS drug exposure and suggest further research directions so as to optimise medicine use in people with ALS.
25 Sep 2021Submitted to British Journal of Pharmacology
27 Sep 2021Submission Checks Completed
27 Sep 2021Assigned to Editor
29 Sep 2021Reviewer(s) Assigned
24 Oct 2021Review(s) Completed, Editorial Evaluation Pending
27 Oct 2021Editorial Decision: Revise Minor
23 Nov 20211st Revision Received
24 Nov 2021Submission Checks Completed
24 Nov 2021Assigned to Editor
25 Nov 2021Reviewer(s) Assigned
23 Dec 2021Review(s) Completed, Editorial Evaluation Pending
27 Dec 2021Editorial Decision: Revise Minor
27 Dec 20212nd Revision Received
28 Dec 2021Submission Checks Completed
28 Dec 2021Assigned to Editor
29 Dec 2021Review(s) Completed, Editorial Evaluation Pending
29 Dec 2021Editorial Decision: Accept
Jun 2022Published in British Journal of Pharmacology volume 179 issue 11 on pages 2577-2588. 10.1111/bph.15802